Tubulysin C is primarily investigated for its potent anticancer properties. It works by disrupting microtubule dynamics, which are crucial for cell division, making it highly effective in inhibiting the growth of cancer cells. Due to its mechanism of action, it is being studied as a potential component in targeted cancer therapies, particularly for treating solid tumors and drug-resistant cancers. Researchers are also exploring its use in antibody-drug conjugates (ADCs), where it can be delivered directly to cancer cells, minimizing damage to healthy tissues. Its high cytotoxicity makes it a promising candidate for advanced oncology treatments, though further research is needed to fully understand its efficacy and safety.